- Report Published -
|House Bill 240 (1994) Mandated Offer of Coverage for the Treatment of Breast Cancer by Autologous Bone Marrow or Stem Cell Transplant|
|Special Advisory Commission on Mandated Health Insurance Benefits|
|The report contained herein has been prepared pursuant to §§ 9-298 and 9-299 of the Code of Virginia.|
This report documents a study conducted by the Special Advisory Commission on Mandated Health Insurance Benefits to assess the social and financial impact and the medical efficacy of House Bill 240 (1994 Session) regarding a proposed mandated offer of coverage for the treatment of breast cancer with high dose chemotherapy and autologous bone marrow or stem cell transplantation.
House Bill 240 was referred to the Special Advisory Commission on Mandated Health Insurance Benefits (Advisory Commission) for evaluation by the Joint Commission on Health Care. House Bill 240 is patroned by Delegate Mary T. Christian and requires that insurers offer and make available coverage for the treatment of breast cancer with high dose chemotherapy and autologous bone marrow or stem cell transplantation.
On January 19, 1994, the Advisory Commission held a public hearing to receive comments from all interested parties regarding House Bill 240. Written comments were received prior to the public hearing from several interested parties. Twenty-four (24) speakers provided oral comments at the hearing.